HealthEquity, Inc. (NASDAQ:HQY) Stock Holdings Increased by Mackenzie Financial Corp

Mackenzie Financial Corp grew its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 58.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,807,407 shares of the company's stock after purchasing an additional 664,979 shares during the quarter. Mackenzie Financial Corp owned approximately 2.11% of HealthEquity worth $119,831,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in HQY. FMR LLC grew its stake in HealthEquity by 19.1% in the 3rd quarter. FMR LLC now owns 5,648,992 shares of the company's stock valued at $412,659,000 after acquiring an additional 907,743 shares during the period. Norges Bank purchased a new stake in HealthEquity in the fourth quarter valued at $34,071,000. BlackRock Inc. increased its position in shares of HealthEquity by 4.0% during the 1st quarter. BlackRock Inc. now owns 9,423,008 shares of the company's stock worth $635,488,000 after purchasing an additional 358,743 shares during the last quarter. JPMorgan Chase & Co. lifted its position in HealthEquity by 15.5% in the first quarter. JPMorgan Chase & Co. now owns 2,474,430 shares of the company's stock valued at $145,273,000 after buying an additional 331,735 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of HealthEquity by 164.6% in the 3rd quarter. Invesco Ltd. now owns 484,043 shares of the company's stock valued at $35,359,000 after acquiring an additional 301,078 shares during the period. Institutional investors and hedge funds own 99.55% of the company's stock.

Wall Street Analysts Forecast Growth

HQY has been the subject of several research reports. Bank of America lifted their target price on HealthEquity from $93.00 to $97.00 and gave the company a "buy" rating in a research report on Wednesday, March 20th. Royal Bank of Canada upped their price objective on HealthEquity from $90.00 to $92.00 and gave the stock an "outperform" rating in a research report on Wednesday, March 20th. Barrington Research reiterated an "outperform" rating and issued a $100.00 target price on shares of HealthEquity in a report on Friday, March 22nd. BTIG Research boosted their target price on HealthEquity from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, March 20th. Finally, Barclays increased their price target on HealthEquity from $84.00 to $104.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $96.17.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, CEO Jon Kessler sold 33,765 shares of the company's stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the completion of the sale, the chief executive officer now directly owns 126,635 shares of the company's stock, valued at approximately $10,106,739.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Evelyn S. Dilsaver sold 32,500 shares of the stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total transaction of $2,576,925.00. Following the completion of the transaction, the director now directly owns 32,123 shares of the company's stock, valued at approximately $2,547,032.67. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jon Kessler sold 33,765 shares of the stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $79.81, for a total value of $2,694,784.65. Following the transaction, the chief executive officer now directly owns 126,635 shares of the company's stock, valued at $10,106,739.35. The disclosure for this sale can be found here. Insiders sold a total of 71,322 shares of company stock valued at $5,682,895 in the last ninety days. Insiders own 2.70% of the company's stock.

HealthEquity Stock Performance

Shares of NASDAQ HQY traded up $0.04 during trading hours on Tuesday, reaching $80.27. The stock had a trading volume of 528,479 shares, compared to its average volume of 608,818. The firm has a market cap of $6.89 billion, a price-to-earnings ratio of 126.64, a PEG ratio of 1.30 and a beta of 0.53. The company has a current ratio of 4.76, a quick ratio of 4.76 and a debt-to-equity ratio of 0.43. HealthEquity, Inc. has a fifty-two week low of $48.86 and a fifty-two week high of $84.49. The firm has a 50-day moving average of $80.90 and a 200-day moving average of $74.08.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.42 by $0.08. The firm had revenue of $262.39 million during the quarter, compared to analysts' expectations of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. Equities research analysts predict that HealthEquity, Inc. will post 2.12 earnings per share for the current year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.